申请人:ORYZON GENOMICS S.A.
公开号:US10202330B2
公开(公告)日:2019-02-12
The present invention relates to a compound of Formula 1, wherein: (A) is heteroaryl or aryl; each (A′), if present, is independently chosen from aryl, arylalkoxy, arylalkyl, heterocyclyl, aryloxy, halo, alkoxy, haloalkyl, cycloalkyl, haloalkoxy, and cyano, wherein each (A′) is substituted with 0, 1, 2, or 3 substituents independently chosen from halo, haloalkyl, haloalkoxy, aryl, arylalkoxy, alkyl, alkoxy, amido, —CH2C(=0)NH2, heteroaryl, cyano, sulfonyl, and sulfinyl; X is 0, 1, 2, or 3; (B) is a cyclopropyl ring, wherein (A) and (Z) are covalently bonded to different carbon atoms of (B); (Z) is —NH—; (L) is chosen from a single bond, —CH2—, —CH2CH2—, —CH2CH2CH2—, and —CH2CH2CH2CH2—; and (D) is an aliphatic carbocyclic group or benzocycloalkyl, wherein said aliphatic carbocyclic group or said benzocycloalkyl has 0, 1, 2, or 3 substituents independently chosen from —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)(C1-C6 alkyl), alkyl, halo, amido, cyano, alkoxy, haloalkyl, and haloalkoxy. (A′)X-(A)-(B)—(Z)-(L)-(D) formula (I) The compounds of the invention show activity for inhibiting LSD1, which makes them useful in the treatment or prevention of diseases such as cancer.
本发明涉及式 1 的化合物,其中:(A)是杂芳基或芳基;每个(A′)(如果存在)独立地选自芳基、芳烷氧基、芳烷基、杂环基、芳氧基、卤代、烷氧基、卤代烷基、环烷基、卤代烷氧基和氰基,其中每个(A′)被 0、1、2 或 3 个取代基,这些取代基独立选自卤代、卤代烷基、卤代烷氧基、芳基、芳基烷氧基、烷基、烷氧基、氨基、-CH2C(=0)NH2、杂芳基、氰基、磺酰基和亚砜基;X 是 0、1、2 或 3;(B) 是环丙基环,其中(A)和(Z)与(B)的不同碳原子共价键合;(Z)是-NH-;(L)选自单键、-CH2-、-CH2CH2-、-CH2CH2CH2-和-CH2CH2CH2-;和 (D) 是脂肪族碳环基团或苯并环烷基,其中所述脂肪族碳环基团或所述苯并环烷基具有 0、1、2 或 3 个取代基,这些取代基独立选自-NH2、-NH(C1-C6 烷基)、-N(C1-C6 烷基)(C1-C6 烷基)、烷基、卤代、氨基、氰基、烷氧基、卤代烷基和卤代烷氧基。(A′)X-(A)-(B)-(Z)-(L)-(D) 式(I) 本发明的化合物显示出抑制 LSD1 的活性,这使它们在治疗或预防癌症等疾病中有用。